- Home
- FACTW vs GLPG Comparison
FACTW vs GLPG Comparison
Compare FACTW & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FACTW
- GLPG
- Stock Information
- Founded
- FACTW N/A
- GLPG 1999
- Country
- FACTW United States
- GLPG Belgium
- Employees
- FACTW N/A
- GLPG N/A
- Industry
- FACTW
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- FACTW
- GLPG Health Care
- Exchange
- FACTW Nasdaq
- GLPG Nasdaq
- Market Cap
- FACTW N/A
- GLPG 1.6B
- IPO Year
- FACTW N/A
- GLPG 2005
- Fundamental
- Price
- FACTW N/A
- GLPG $22.67
- Analyst Decision
- FACTW
- GLPG Hold
- Analyst Count
- FACTW 0
- GLPG 5
- Target Price
- FACTW N/A
- GLPG $30.75
- AVG Volume (30 Days)
- FACTW N/A
- GLPG 303.6K
- Earning Date
- FACTW N/A
- GLPG 02-12-2025
- Dividend Yield
- FACTW N/A
- GLPG N/A
- EPS Growth
- FACTW N/A
- GLPG N/A
- EPS
- FACTW N/A
- GLPG 3.50
- Revenue
- FACTW N/A
- GLPG $290,089,226.00
- Revenue This Year
- FACTW N/A
- GLPG $32.98
- Revenue Next Year
- FACTW N/A
- GLPG N/A
- P/E Ratio
- FACTW N/A
- GLPG $6.54
- Revenue Growth
- FACTW N/A
- GLPG N/A
- 52 Week Low
- FACTW N/A
- GLPG $22.58
- 52 Week High
- FACTW N/A
- GLPG $40.34
- Technical
- Relative Strength Index (RSI)
- FACTW N/A
- GLPG 23.76
- Support Level
- FACTW N/A
- GLPG $22.90
- Resistance Level
- FACTW N/A
- GLPG $24.04
- Average True Range (ATR)
- FACTW 0.00
- GLPG 0.44
- MACD
- FACTW 0.00
- GLPG -0.09
- Stochastic Oscillator
- FACTW 0.00
- GLPG 11.50
About FACTW FACT II Acquisition Corp. Warrant
FACT II Acquisition Corp is a blank check company.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.